CD34 and neoplasm: Given the expression of CD133 by a proportion of normal primitive HSPCs (supplemental Figure 1D), we used a humanized xenograft model to assess potential off-tumor effects of CD19-CD133 bispecific CAR-iNKT cells by transplanting cord blood CD34+ cells into sublethally irradiated NSG-SGM3 mice (Figure 7A).